Latest Share Chat

ORPH.L Share News (ORPH)

ORPH.L Information

There is currently no data for ORPH

IN BRIEF: Open Orphan non-exec Mo Khan switches to chief executive

Thu, 24th Feb 2022 14:48

Open Orphan PLC - London-based pharmaceutical services - Moves Non-Executive Director Mo Khan to chief executive officer, effective immediately. Khan had joined the Open Orphan board back in October. The company notes he has 25 years of clinical research experience. Cathal Friel remains executive chair, while Open Orphan will aim to find a new independent non-executive director within the next six months.

Current stock price: 13.53 pence, down 9.8% on Thursday

12-month change: down 50%

By Tom Waite; thomaslwaite@alliancenews.com

More News

17 Jan 2020 10:51

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

16 Jan 2020 18:15

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

14 Jan 2020 16:10

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

6 Jan 2020 17:29

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

6 Jan 2020 11:49

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

6 Jan 2020 10:55

Open Orphan inks three-year contract with mystery European firm

(Sharecast News) - Drug consulting services platform Open Orphan has won a new three-year contract with an unnamed German pharmaceutical company.

31 Dec 2019 09:46

Open Orphan Meets Acceptance Condition For Merger With hVIVO

31 Dec 2019 06:31

UK Shareholder Meetings Calendar - Next 7 Days

18 Dec 2019 12:54

Open Orphan signs deal with US biopharmaceutical firm SFA

(Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, on Wednesday.

18 Dec 2019 12:29

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

9 Dec 2019 14:36

Open Orphan agrees acquisition of hVIVO at 34% premium

(Sharecast News) - Open Orphan, the rare and orphan drug services company, has agreed the takeover of hVIVO by means of an all-share reverse take-over at a 33.8% premium.

9 Dec 2019 11:23

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

25 Nov 2019 14:57

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

18 Nov 2019 10:35

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

18 Nov 2019 09:58

Open Orphan signs pharmacology trial contract with Carna

(Sharecast News) - Rare and orphan drug consulting services provider Open Orphan announced the signing of a contract with Carna Bioscience for a first-in-human clinical pharmacology trial, it announced on Monday.

Latest Share Chat

ORPH.L Share News (ORPH)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Open Orphan non-exec Mo Khan switches to chief executive

Login to your account

Quickpicks are a member only feature

Login to your account